

GLG LIFE TECH CORPORATION

MANAGEMENT DISCUSSION & ANALYSIS For the Three Months Ended March 31, 2020 Dated: June 25, 2020

Management's Discussion and Analysis

This Management's Discussion and Analysis ("MD&A") of GLG Life Tech Corporation is dated June 25, 2020. It provides a review of the financial results for the three months ended March 31, 2020, compared to the same period in the prior year.

This MD&A relates to the consolidated financial condition and results of operations of GLG Life Tech Corporation ("we," "us," "our," "GLG" or the "Company") together with GLG's subsidiaries in the People's Republic of China ("China") and other jurisdictions. As used herein, the word "Company" means, as the context requires, GLG and its subsidiaries. The common shares of GLG are listed on the Toronto Stock Exchange (the "Exchange") under the symbol "GLG". Except where otherwise indicated, all financial information reflected herein is expressed in Canadian dollars and determined on the basis of International Financial Reporting Standards ("IFRS"). This MD&A should be read in conjunction with the condensed interim consolidated financial statements and notes thereto for the three months ended March 31, 2020, as well as the annual consolidated financial information relating to GLG Life Tech Corporation including GLG's Annual Information Form can be found on GLG's web site at www.glglifetech.com or on the SEDAR web site for Canadian regulatory filings at www.sedar.com.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting period, which could result in a material adjustment to the carrying amounts of assets and liabilities and disclosure of contingent assets or liabilities in the event that actual results differ from assumptions made, relate to, but are not limited to, the following: determining the accrued liabilities; assessing the fair value of property, plants and equipment, biological assets, intangible assets and goodwill; the valuation of future tax assets; revenue recognition; estimate of inventory net realizable value; going concern assumption; expected useful lives of assets subject to amortization and the assumptions used in determining the fair value of stock-based compensation. While management believes the estimates used are reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows.

GLG has issued reports on certain non-IFRS measures that are used by management to evaluate the Company's performance. Because non-IFRS measures do not have a standardized meaning, securities regulations require that non-IFRS measures be clearly defined and qualified and reconciled with their nearest IFRS measure. Where non-IFRS measures are reported, GLG has provided the definition and reconciliation to their nearest IFRS measure in the section "NON-IFRS Financial Measures".

Forward-Looking Statements

Certain statements in this MD&A constitute "forward-looking statements" and "forward looking information" (collectively, "forward-looking statements") within the meaning of applicable securities laws. Such forward-looking statements include, without limitation, statements evaluating the market, statements regarding potential demand for stevia, Monk fruit, and other products and discussions regarding general economic conditions and future-oriented costs and expenditures. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or words and phrases that state or indicate that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.

While the Company has based these forward-looking statements on its current expectations about future events, the statements are not guarantees of the Company's future performance and are subject to risks, uncertainties,

assumptions and other factors which could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Such factors include amongst others the effects of general economic conditions, consumer demand for our products and new orders from our customers and distributors, changing foreign exchange rates and actions by government authorities, uncertainties associated with legal proceedings and negotiations, industry supply levels, competitive pricing pressures and misjudgments in the course of preparing forward-looking statements. Specific reference is made to the risks described herein under the heading "Risks Related to the Company's Business" and "Risks Associated with Doing Business in the People's Republic of China" for a discussion of these and other sources of factors underlying forward-looking statements and to those additional risks set forth under the heading "Risk Factors" in the Company's Annual Information Form for the financial year ended December 31, 2019. In light of these factors, the forward-looking events discussed in this MD&A might not occur.

Further, although the Company has attempted to identify factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

As there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements, readers should not place undue reliance on forward-looking statements.

Financial outlook information contained in this MD&A about prospective results of operations, capital expenditures or financial positions is based on assumptions about future events, including economic conditions and proposed courses of action, based on management's assessment of the relevant information as of the date hereof. Such financial outlook information should not be used for purposes other than those for which it is disclosed herein.

Overview

We are a leading producer of high-quality stevia extract and high-quality monk fruit extract. While stevia has long been the foundation of our company, over the last five years we have been producing and selling monk fruit extracts to the international market. Stevia extracts, such as Rebaudioside A (or Reb A), and monk fruit extracts are used as all-natural, zero-calorie sweeteners in food and beverages. Our revenue presently derives primarily from the sale of high-grade stevia extract to the food and beverage industry; the expansion into monk fruit extracts represents an additional significant source of actual and potential revenues. Furthermore, we have expanded our product offerings and market opportunities through the supply of ingredients complementary to the natural high-intensity sweetener market under our Naturals+ product line.

We conduct our stevia and monk fruit development, refining, processing and manufacturing operations through a 67.08% owned subsidiary in China. Our stevia operations in China include four processing factories, stevia growing areas across 10 growing regions, and four research and development centers engaged in the development of high-yielding stevia seeds and seedlings. Our processing facilities have a combined annual throughput of 41,000 metric tons of stevia leaf, over 1,500 metric tons of high-purity stevia extract, and 130 metric tons of high-purity monk fruit extract.

Corporate and Sales Developments

Resignation and Replacement of Chief Financial Officer

Mr. Finnsson, the Company's CFO since March of 2019, has tendered his resignation, for personal reasons, effective June 30, 2020. Management thanks Mr. Finnsson for his service. The Company has appointed Mr. Edward Wang, the Company's current Controller, as Acting Chief Financial Officer.

Issuance and Revocation of Management Cease Trade Order

Due to a previously announced delay in filing of the Company's 2019 year-end financial statements and related documents, such delay arising from the impact of COVID-19 on the Company's ability to timely complete the filing, on May 15, 2020, the Company announced that it had applied for and been issued a Management Cease Trade Order ("MCTO") by the relevant securities commissions. Shortly after completing the filing, the MCTO was revoked on June 8, 2020.

Company Outlook

One of the most critical items that management has focused on and continues to focus on is the development and implementation of plans to stem the losses that the Company has suffered in recent years and to ameliorate the Company's financial position. As a result of those sustained losses, the Company lacks the cash necessary to fully fund the business operations and its strategic product initiatives. The Company is managing its cash flows carefully to mitigate risk of insolvency. Management has been successful in improving the Company's cash outlook in recent quarters. Nevertheless, without an infusion of cash in the months ahead, the Company may not be able to realize its strategic plans and could eventually cease to be a going concern.

To address that cash need, management has negotiated a CAD \$1 million revolving loan facility with a related party for working capital purposes in 2020. Management has also prioritized the sale of its idle assets either to generate cash, significantly improve the Company's balance sheet, or both. Management expects that it will close on the sale of its idle Qingdao "Runhao" secondary purification facility in the third quarter of 2020, although there is uncertainty as to that timing as well as to the final closing of the deal. Upon closing, Management expects that the Company will extinguish a significant portion of the debt held by China Cinda Assets Management (which owns 98% of the Company's Chinese bank debt) and a related party. Management is also

evaluating options for the sale of its idle "Runyang" primary processing facility in Jiangsu province to further address its cash needs and balance sheet.

Another factor contributing to the Company's financial situation is the competitive price pressure in the stevia market over the last year that has reduced mainstream "Reb A" products (such as Reb A 80 and Reb A 97) to the lowest price levels in years. While these products have historically formed the core of the Company's product sales, the margins on sales of these products have grown increasingly slim. To address this, the Company is taking a three-pronged approach.

First, the Company has taken decisive steps to reduce its SG&A costs as well as its production costs. Its North American operations have already reduced SG&A costs and the Company is in the process of eliminating nonessential costs in its Chinese operations. For the last several years, the Company's production capacity has been far greater than its projected order levels as it had sought rapid increases in orders for Reb A products. The Company's goal is now to "right-size" its Chinese operations – i.e., to optimize its staffing and production planning to meet the Company's projected production requirements while retaining the ability to accommodate growth in future order volumes. Management expects that this will enable the Company to sell its goods at more competitive and/or more profitable prices to secure additional order volumes and/or retain additional margin.

Second, the Company is increasing its focus on specialty stevia products, relative to its Reb A products. These specialty products are more differentiated than Reb A products and can bring more revenue opportunities and more meaningful margin contributions to the Company's bottom line. The Company is also progressing well on implementing a new line of business in the sweetener space distinct from its bulk stevia sales that has the potential to significantly increase the Company's revenues and margins.

Third, the Company is exploring options to enter the CBD market, where it could leverage its production expertise and equipment towards an investment that would jump start its ability to quickly begin producing high-quality low-cost CBD products. The Company has also entered into a distributorship agreement with East West Pharma Group for the distribution of its high-quality cannabidiol ("CBD") products and continues to explore other complementary opportunities in the cannabis extract market. While the Company does not expect to begin any CBD operations or sales in the first half of 2020, it is anticipating revenues and margins in the second half of 2020 and beyond.

While the Company continues to face substantial risks and 2020 remains a pivotal year for the Company, management remains optimistic about the future opportunities for the Company. With the expected land sale heading towards closing, right-sizing efforts underway, the optimization of production efficiencies, costs, and planning, and the Company's refocused product strategies, management is proceeding down the best available path to increased financial stability and profitability.

Results from Operations

The following results from operations have been derived from and should be read in conjunction with the Company's annual consolidated financial statements for 2019 and the condensed interim consolidated financial statements for the three-month period ended March 31, 2020.

In thousands Canadian \$, except per share amounts	3 Months En	ded March 31	% Change
	2020	2019	
Revenue	\$2,565	\$2,023	27%
Cost of Sales	(\$2,254)	(\$1,946)	16%
% of Revenue	(88%)	(96%)	8%
Gross Profit (Loss)	\$311	\$77	304%
% of Revenue	12%	4%	8%
Expenses	(\$1,627)	(\$2,267)	(28%)
% of Revenue	(63%)	(112%)	49%
(Loss) from Operations	(\$1,316)	(\$2,190)	(40%)
% of Revenue	(51%)	(108%)	57%
Other Expenses	(\$8,495)	(\$4,106)	107%
% of Revenue	(331%)	(203%)	(128%)
Net (Loss) before Income Taxes	(\$9,811)	(\$6,296)	56%
% of Revenue	(382%)	(311%)	(71%)
Net (Loss)	(\$9,811)	(\$6,296)	56%
% of Revenue	(382%)	(311%)	(71%)
Net (Loss) Attributable to Non-Controlling Interest (NCI)	(\$1,133)	(\$1,496)	(24%)
Net (Loss) Attributable to GLG	(\$8,678)	(\$4,800)	81%
% of Revenue	(338%)	(237%)	(101%)
Loss per share (LPS, Basic & Diluted)	(\$0.23)	(\$0.12)	84%
Other Comprehensive Income	(\$5,399)	(\$565)	856%
% of Revenue	(210%)	(28%)	(183%)
Comprehensive Loss	(\$15,210)	(\$6,861)	122%
Comprehensive Loss Attributable to NCI	(\$3,022)	(\$1,687)	79%
Comprehensive Loss Attributable to GLG	(\$12,188)	(\$5,174)	136%
% of Revenue	(475%)	(256%)	(219%)

Revenue

Revenue for the three months ended March 31, 2020, was \$2.6 million compared to \$2.0 million in revenue for the same period last year. Sales increased by 27% or \$0.5 million for the period ending March 31, 2020, compared to the prior period. The sales increase of \$0.5 million was driven primarily by a 27% increase in international stevia sales; a 72% increase in international monk fruit sales also contributed (monk fruit sales make up a relatively small percentage of overall sales). International sales continue to be the predominant component of the Company's revenues (93% in first quarter 2020 versus 92% in first quarter 2019).

Cost of Sales

For the quarter ended March 31, 2020, the cost of sales was \$2.3 million compared to \$1.9 million in cost of sales for the same period last year (\$0.3 million or 16% decrease). Cost of sales as a percentage of revenues was 88% for the first quarter 2020, compared to 96% for the comparable period, an improvement of 8 percentage points.

The decrease in cost of sales as a percentage of revenue for the three months ended March 31, 2020, compared to the prior comparable period, is primarily attributable to a change in mix of products sold, with a greater percentage of sales of higher-margin stevia products, and improvements in cost management and production efficiency, as well as a decrease in idle capacity charges in the first quarter of 2020 compared to the first quarter of 2019; these favorable factors were partly offset by a relative increase in cost of sales of monk fruit and China stevia sales each measured as a percentage of revenues for the first quarter of 2020 compared to the first quarter of 2019.

Capacity charges charged to the cost of sales ordinarily would flow to inventory and are a significant component of the cost of sales. Only two of GLG's manufacturing facilities were operating during the first quarter of 2020, and capacity charges of \$0.5 million were charged to cost of sales (representing 22% of cost of sales) compared to \$0.5 million charged to cost of sales in the same period of 2019 (representing 27% of cost of sales).

The key factors that impact stevia and monk fruit cost of sales and gross profit percentages in each period include:

- 1. Capacity utilization of stevia and monk fruit manufacturing plants.
- 2. The price paid for stevia leaf and monk fruit, and their respective quality which is impacted by crop quality for a particular year/period, and the price per kilogram for which the stevia and monk fruit extracts are sold. These are the most important factors that will impact the gross profit of GLG's stevia and monk fruit business.
- 3. Other factors which also impact stevia and monk fruit cost of sales to a lesser degree include:
 - water and power consumption;
 - manufacturing overhead used in the production of stevia and monk fruit extract, including supplies, power and water;
 - net VAT paid on export sales;
 - exchange rate changes; and
 - depreciation and capacity utilization of the extract processing plants.

GLG's stevia and monk fruit businesses are affected by seasonality. The harvest of the stevia leaves typically occurs starting at the end of July and continues through the fall of each year. The monk fruit harvest takes place typically from October to December each year. GLG's operations in China are also impacted by Chinese New Year celebrations, which occur approximately late-January to mid-February each year, and during which many businesses close down operations for approximately two weeks. GLG's production year runs October 1 through September 30 each year.

Gross Profit (Loss)

Gross profit for the three months ended March 31, 2020, was \$0.3 million, compared to a gross profit of \$0.1 million for the comparable period in 2019. The gross profit margin was 12% in the first quarter of 2020 compared to 4% for the same period in 2019, an increase of 8 percentage points. This 8 percentage point increase in gross profit margin for the first quarter of 2020, relative to the comparable period in 2019, is primarily

attributable to a change in mix of products sold, with a greater percentage of sales of higher-margin stevia products, and improvements in cost management and production efficiency, as well as a decrease in idle capacity charges in the first quarter of 2020 compared to the first quarter of 2019; these favorable factors were partly offset by a relative increase in cost of sales of monk fruit and China stevia sales when measured as a percentage of revenues for the first quarter of 2020 compared to the first quarter of 2019.

Selling, General, and Administration Expenses

Selling, General and Administration ("SG&A") expenses include sales, marketing, general and administration costs ("G&A"), stock-based compensation, and depreciation and amortization expenses on G&A fixed assets. A breakdown of SG&A expenses into these components is presented below:

In thousands Canadian \$	3 Months End	ed March 31	% Change
	2020	2019	
G&A Expenses	\$1,274	\$1,866	(32%)
Stock Based Compensation Expenses	\$149	\$149	(%)
Depreciation Expenses	\$203	\$251	(19%)
Total	\$1,627	\$2,267	(28%)

G&A expenses for the three months ended March 31, 2020, were \$1.3 million, a decrease of \$0.6 million compared to \$1.9 million in the same period in 2019. The \$0.6 million decrease in G&A expenses was driven primarily by reductions in salary expenses, research and development expenses, professional fees and office expenses.

Stock-based compensation for the three months ended March 31, 2020, was flat at \$0.1 million compared to the same period in 2019.

The number of common shares available for issue under the stock compensation plan is 10% of the issued and outstanding common shares. During the quarter, compensation from vesting stock-based compensation awards was recognized, due to previously granted restricted shares.

G&A-related depreciation and amortization expenses for the three months ended March 31, 2020, were \$0.2 million compared with \$0.3 million for the same quarter of 2019.

Other Expenses

In thousands Canadian \$	3 Months End	led March 31	% Change
	2020	2019	
Other (Expenses)	(\$8,495)	(\$4,106)	107%
% of Revenue	(331%)	(203%)	(128%)

Other expenses for the three months ended March 31, 2020, was \$8.5 million, compared to \$4.1 million for the same period in 2019, an increase of \$4.4 million or 27%. This \$4.4 million increase in other expenses for the quarter was driven by (1) an increase in foreign exchange loss (\$4.2 million) and (2) an increase in interest expenses (\$0.7 million), which were offset by (3) a decrease in other expenses (\$0.3 million) and (4) a net increase in increase in increase in increase (\$0.2 million).

Foreign Exchange Gains (Losses)

Exchange rates	2020	2019	2019	2019	2019	2018	2018	2018
Rate (as compared to the Canadian \$)	31-Mar	31-Dec	30-Sep	30-Jun	31-Mar	31-Dec	30-Sep	30-Jun
U.S. Dollars	0.7049	0.7699	0.7551	0.7641	0.7483	0.7330	0.7725	0.7594
Chinese RMB	4.9950	5.3619	5.3967	5.2466	5.0226	5.0429	5.3079	5.0277
Exchange rates	2020	2019	2019	2019	2019	2018	2018	2018
Rate (as compared to the US \$)	31-Mar	31-Dec	30-Sep	30-Jun	31-Mar	31-Dec	30-Sep	30-Jun
Chinese RM B	7.0864	6.9641	7.1468	6.8664	6.7111	6.8764	6.8665	6.6191

GLG reports in Canadian dollars but earns revenues in US dollars and Chinese renminbi ("RMB") and incurs most of its expenses in RMB. Impacts of the appreciation or depreciation of the RMB against the Canadian dollar are shown separately in Accumulated Other Comprehensive Loss ("AOCL") on the Balance Sheet. As at March 31, 2020, the exchange rate for RMB per Canadian dollar was 4.9950 compared to the exchange rate of 5.3619 as at December 31, 2019, reflecting an appreciation of the RMB against the Canadian dollar. As at March 31, 2020, the exchange rate for USD per Canadian dollar was 0.7049 compared to the exchange rate of 0.7699 as at December 31, 2019, reflecting an appreciation of the USD against the Canadian dollar. The balance of the AOCL was \$7.5 million on March 31, 2020, compared to a balance of \$11.0 million as at December 31, 2019.

The foreign exchange gain or loss is made up of realized and unrealized gains or losses due to the depreciation or appreciation of the foreign currency against the Canadian dollar. Foreign exchange loss was \$4.0 million for the first quarter of 2020 compared to the foreign exchange gain of \$0.2 million for the comparable period in 2019. The table above shows the change in the Canadian dollar relative to the US dollar from June 30, 2018, to March 31, 2020, and the exchange rate movement for the Canadian dollar relative to the US dollar and RMB as shown above.

In thousands Canadian \$	3 Months E	Ended March 31	% Change
	2020	2019	
Net Loss	(\$9,811)	(\$6,296)	56%
Net Loss Attributable to NCI	(\$1,133)	(\$1,496)	(24%)
% of Revenue	(44%)	(74%)	30%
Net Loss Attributable to GLG	(\$8,678)	(\$4,800)	81%
% of Revenue	(338%)	(237%)	(101%)

Net Loss Attributable to the Company

For the three months ended March 31, 2020, the Company had a net loss attributable to the Company of \$8.7 million, an increase of \$3.9 million or 81% over the comparable period in 2019 (\$4.8 million). The \$3.9 million increase in net loss attributable to the Company was driven by (1) an increase in other expenses (\$4.4 million) and (2) a decrease in net loss attributable to non-controlling interests (\$0.4 million), which were offset by (3) a decrease in loss from operations (\$0.9 million).

Comprehensive Loss

In thousands Canadian \$	3 Months End	led March 31	% Change
	2020	2019	
Other Comprehensive Income	(\$5,399)	(\$565)	856%
Total Comprehensive Loss	(\$15,210)	(\$6,861)	122%
Comprehensive Loss Attributable to NCI	(\$3,022)	(\$1,687)	79%
Comprehensive Loss Attributable to GLG	(\$12,188)	(\$5,174)	136%
% of Revenue	(475%)	(256%)	(219%)

The Company recorded a total comprehensive loss of \$12.2 million for the three months ended March 31, 2020, comprising \$8.7 million of net loss attributable to the Company and \$3.5 million of other comprehensive loss attributable to the Company. The Company recorded total comprehensive loss of \$5.2 million for the three months ended March 31, 2019, comprising \$4.8 million of net loss attributable to the Company and \$0.4 million of other comprehensive loss attributable to the Company.

Summary of Quarterly Results

The selected consolidated information below has been gathered from GLG's quarterly condensed interim consolidated financial statements for the previous eight quarterly periods:

Quarterly Net Loss

In thousands Canadian \$, except per share amounts	2020 Q1	2019 Q4	2019 Q3	2019 Q2	2019 Q1	2018 Q4	2018 Q3	2018 Q2
Revenue	\$2,565	\$2,928	\$2,373	\$2,827	\$2,023	\$3,792	\$2,496	\$6,027
Gross Profit \$	\$311	\$185	\$444	\$851	\$77	\$513	\$47	\$1,051
Gross Profit %	12%	6%	19%	30%	4%	14%	2%	17%
Net Income (Loss) Attributable to GLG	(\$8,678)	(\$7,785)	(\$3,858)	(\$2,849)	(\$4,799)	(\$10,311)	(\$2,482)	(\$3,142)
Basic Income (Loss) Per Share	(\$0.23)	(\$0.20)	(\$0.10)	(\$0.07)	(\$0.12)	(\$0.27)	(\$0.06)	(\$0.08)

For the three months ended March 31, 2020, the Company had a net loss attributable to the Company of \$8.7 million, an increase of \$3.9 million or 81% over the comparable period in 2019 (\$4.8 million). The \$3.9 million increase in net loss attributable to the Company was driven by (1) an increase in other expenses (\$4.4 million) and (2) a decrease in net loss attributable to non-controlling interests (\$0.4 million), which were offset by (3) a decrease in loss from operations (\$0.9 million).

For the three months ended December 31, 2019, the Company had a net loss attributable to the Company of \$7.8 million, a decrease of \$2.5 million or 24% over the comparable period in 2018 (\$10.3 million). The \$2.5 million decrease in net loss attributable to the Company was driven by (1) a decrease in loss from operations (\$0.3 million) and (2) a decrease in other expenses (\$3.1 million), which were offset by (3) a decrease in net loss attributable to non-controlling interests (\$0.9 million).

For the three months ended September 30, 2019, the Company had a net loss attributable to the Company of \$3.9 million, an increase of \$1.4 million or 56% over the comparable period in 2018 (\$2.5 million). The \$1.4 million increase in net loss attributable to the Company was driven by (1) an increase in other expenses (\$2.5 million), which was offset by (2) a decrease in loss from operations (\$1.0 million) and (3) an increase in net loss attributable to some the company.

For the three months ended June 30, 2019, the Company had a net loss attributable to the Company of \$2.8 million, a decrease of \$0.3 million or 9% over the comparable period in 2018 (\$3.1 million). The \$0.3 million

decrease in net loss was driven by (1) an increase in net loss attributable to non-controlling interests (\$0.6 million), which was offset by (2) an increase in net loss (\$0.3 million).

For the three months ended March 31, 2019, the Company had a net loss attributable to the Company of \$4.8 million, a decrease of \$0.8 million or 15% over the comparable period in 2018 (\$5.6 million). The \$0.8 million decrease in net loss was driven by (1) an increase in net losses attributable to non-controlling interests (\$1.0 million), which were offset by (2) a decrease in gross profit (\$0.2 million).

For the three months ended December 31, 2018, the Company had a net loss attributable to the Company of \$10.3 million, an increase of \$5.6 million or a 119% increase over the comparable period in 2017 (\$4.7 million loss). The \$5.6 million increase in net loss attributable to the Company was driven by increases in (1) other expenses (\$7.6 million) and (2) SG&A expenses (\$1.3 million), which were offset by increases in (3) gross profit (\$0.5 million) and (4) net loss attributable to the non-controlling interest (\$2.8 million).

For the three months ended September 30, 2018, the Company had a net loss attributable to the Company of \$2.5 million, a decrease of \$1.3 million or a 35% improvement over the comparable period in 2017 (\$3.8 million loss). The \$1.3 million decrease in net loss was driven by increases in (1) gross profit (\$0.3 million) and (2) net loss attributable to the non-controlling interest (\$0.4 million) and decreases in (3) SG&A expenses (\$0.2 million) and (4) other expenses (\$0.4 million).

For the three months ended June 30, 2018, the Company had a net loss attributable to the Company of \$3.1 million, a decrease of \$0.8 million or a 19% improvement over the comparable period in 2017 (\$3.9 million loss). The \$0.8 million decrease in net loss was driven by (1) an increase in gross profit (\$0.5 million), (2) a decrease in SG&A expenses (\$0.1 million) and (3) an increase in net loss attributable to the non-controlling interest (\$0.4 million), which were offset by (4) an increase in other expenses (\$0.2 million).

Quarterly Basic and Diluted Loss per Share

The basic loss and diluted loss per share from operations was \$0.23 for the three months ended March 31, 2020, compared with a basic and diluted net loss of \$0.12 for the comparable period in 2019. For the three months ended March 31, 2020, the Company had a net loss attributable to the Company of \$8.7 million, an increase of \$3.9 million or 81% over the comparable period in 2019 (\$4.8 million). The \$3.9 million increase in net loss attributable to the Company was driven by (1) an increase in other expenses (\$4.4 million) and (2) a decrease in net loss attributable to non-controlling interests (\$0.4 million), which were offset by (3) a decrease in loss from operations (\$0.9 million).

The basic loss and diluted loss per share from operations was \$0.20 for the three months ended December 31, 2019, compared with a basic and diluted net loss of \$0.27 for the comparable period in 2018. For the three months ended December 31, 2019, the Company had a net loss attributable to the Company of \$7.8 million, a decrease of \$2.5 million or 24% over the comparable period in 2018 (\$10.3 million). The \$2.5 million decrease in net loss attributable to the Company was driven by (1) a decrease in loss from operations (\$0.3 million) and (2) a decrease in other expenses (\$3.1 million), which were offset by (3) a decrease in net loss attributable to non-controlling interests (\$0.9 million).

The basic loss and diluted loss per share from operations was \$0.10 for the three months ended September 30, 2019, compared with a basic and diluted net loss of \$0.06 for the comparable period in 2018. For the three months ended September 30, 2019, the Company had a net loss attributable to the Company of \$3.9 million, an increase of \$1.4 million or 56% over the comparable period in 2018 (\$2.5 million). The \$1.4 million increase in net loss attributable to the Company was driven by (1) an increase in other expenses (\$2.5 million), which was

offset by (2) a decrease in loss from operations (\$1.0 million) and (3) an increase in net loss attributable to noncontrolling interests (\$0.1 million).

The basic loss and diluted loss per share from operations was \$0.07 for the three months ended June 30, 2019, compared with a basic and diluted net loss of \$0.08 for the comparable period in 2018. For the three months ended June 30, 2019, the Company had a net loss attributable to the Company of \$2.8 million, a decrease of \$0.3 million or 9% over the comparable period in 2018 (\$3.1 million). The \$0.3 million decrease in net loss attributable to non-controlling interests (\$0.6 million), which was offset by (2) an increase in net loss (\$0.3 million).

The basic loss and diluted loss per share from operations was \$0.12 for the three months ended March 31, 2019, compared with a basic and diluted net loss of \$0.15 for the comparable period in 2018. For the three months ended March 31, 2019, the Company had a net loss attributable to the Company of \$4.8 million, a decrease of \$0.8 million or 15% over the comparable period in 2018 (\$5.6 million). The \$0.8 million decrease in net loss attributable to non-controlling interests (\$1.0 million), which were offset by (2) a decrease in gross profit (\$0.2 million).

The basic loss and diluted loss per share from operations was \$0.27 for the three months ended December 31, 2018, compared with a basic and diluted net loss of \$0.12 for the comparable period in 2017. For the three months ended December 31, 2018, the Company had a net loss attributable to the Company of \$10.3 million, an increase of \$5.6 million or a 119% increase over the comparable period in 2017 (\$4.7 million loss). The \$5.6 million increase in net loss attributable to the Company was driven by increases in (1) other expenses (\$7.6 million) and (2) SG&A expenses (\$1.3 million), which were offset by increases in (3) gross profit (\$0.5 million) and (4) net loss attributable to the non-controlling interest (\$2.8 million).

The basic loss and diluted loss per share from operations was \$0.06 for the three months ended September 30, 2018, compared with a basic and diluted net loss of \$0.11 for the comparable period in 2017. For the three months ended September 30, 2018, the Company had a net loss attributable to the Company of \$2.5 million, a decrease of \$1.3 million or a 35% improvement over the comparable period in 2017 (\$3.8 million loss). The \$1.3 million decrease in net loss was driven by increases in (1) gross profit (\$0.3 million) and (2) net loss attributable to the non-controlling interest (\$0.4 million) and decreases in (3) SG&A expenses (\$0.2 million) and (4) other expenses (\$0.4 million).

The basic loss and diluted loss per share from operations was \$0.08 for the three months ended June 30, 2018, compared with a basic and diluted net loss of \$0.10 for the comparable period in 2017. For the three months ended June 30, 2018, the Company had a net loss attributable to the Company of \$3.1 million, a decrease of \$0.8 million or a 19% improvement over the comparable period in 2017 (\$3.9 million loss). The \$0.8 million decrease in net loss was driven by (1) an increase in gross profit (\$0.5 million), (2) a decrease in SG&A expenses (\$0.1 million) and (3) an increase in net loss attributable to the non-controlling interest (\$0.4 million), which were offset by (4) an increase in other expenses (\$0.2 million).

NON-IFRS Financial Measures

Gross Profit Before Capacity Charges

This non-IFRS financial measure shows the gross profit (loss) before the impact of idle capacity charges are reflected on the gross profit margin. GLG had only 50% of its production facilities in operation in the first three months of 2020 and idle capacity charges have a material impact on the gross profit (loss) line in the financial statements.

Gross profit before capacity charges for the three months ended March 31, 2020, was \$0.8 million or 31% of first quarter revenues compared to \$0.6 million or 30% of first quarter revenues in 2019. Gross profit before capacity charges for the first three months of 2020 increased from the comparable period due primarily to increased revenues from international stevia sales. Gross profit as a percentage of revenues before capacity charges increased from the comparable period due to a change in mix of products sold, with a greater percentage of sales of higher-margin stevia products, and improvements in cost management and production efficiency; these factors were partly offset by a relative increase in cost of sales of monk fruit and China stevia sales when measured as percentages of revenues for the first quarter of 2020 compared to the first quarter of 2019.

In thousands Canadian \$	3 Months En	% Change	
	2020	2019	
Loss Before Income Taxes	(\$9,811)	(\$6,296)	56%
Add:			
Provisions for Inventories Impairment	(\$65)	\$149	(143%)
Bad Debt (Recoveries for Receivables)	(\$10)	\$0	100%
Depreciation and Amortization	\$508	\$930	(45%)
Net Interest Expense	\$4,393	\$3,728	18%
Foreign Exchange Gain & Loss	\$4,001	(\$198)	(2118%)
Non-Cash Share Compensation	\$149	\$149	(%)
EBITDA	(\$834)	(\$1,538)	(46%)
EBITDA as a % of Revenue	(33%)	(76%)	43%

Earnings Before Interest, Taxes and Depreciation ("EBITDA") and EBITDA Marg

EBITDA for the three months ended March 31, 2020, was negative \$0.8 million or negative 33% of revenues, compared to negative \$1.5 or negative 76% of revenues for the same period in 2019. EBITDA loss decreased by \$0.7 million for the three-month period ended March 31, 2020, relative to the comparable period in 2019, driven primarily by an increase in gross profit and a decrease in SG&A expenses.

Liquidity and Capital Resources

In thousands Canadian \$	31-Mar-20	31-Dec-19
Cash and Cash Equivalents	\$ 8,407	\$ 206
Working Capital	\$ (181,836)	\$ (164,450)
Total Assets	\$ 47,766	\$ 36,652
Total Liabilities	\$ 198,765	\$ 172,591
Loan Payable (<1 year)	\$ 112,942	\$ 101,623
Loan Payable (>1 year)	\$ -	\$ -
Total Shareholder's Deficiency	\$ (119,162)	\$ (107,124)

The Company has several initiatives currently underway in order to manage cash flow, including working closely with the banks to restructure its loans, negotiating the sale of one or more idle assets, and reducing operating expenditures including general and administrative expenses and production-related expenses. The Company also continues to work to reduce accounts receivable, negotiate with creditors for extended payment terms, and arrange financing as necessary with its Directors and other related parties.

Total loans payable (both short-term and long-term) is \$112.9 million as of March 31, 2020, an increase of \$11.3 million compared to the total loans payable as at December 31, 2019 (\$101.6 million). The increase in short-term loans was primarily driven by foreign exchange impacts due to the appreciation of the RMB against the Canadian dollar and an increase in accrued interest on amounts due to related parties.

The Company continued to work with its Chinese banks on restructuring its Chinese debt in 2020. 98% of all China bank loans held by GLG's Chinese subsidiary – Anhui Runhai Biotechnology Joint Stock Company, Ltd. ("Runhai") and its wholly owned Chinese subsidiaries – have been transferred to one state-owned capital management company ("SOCMC"). China Cinda Assets Management ("Cinda") is the sole SOCMC holding the 98% of short-term bank debt. The Company announced in September 2019 a finalized agreement with Cinda to resolve most of its bank debt over a two-year period commencing with the sale of one of its idle assets. The Company expects to finalize this sale in the next few months. The Company also continues to negotiate with Cinda regarding the conversion of outstanding debt into equity in Runhai with a view to participate as an equity shareholder in the potential returns. Cinda could also be a source of possible future capital.

Until the final debt restructuring is completed, the terms of the original loans are represented in the financial statements.

Cash Flows: Three Months Ended March 31, 2020 and 2019

Cash generated by operating activities was \$0.5 million in the three-month period ended March 31, 2020, compared to \$1.0 million used in operating activities in the same period of 2019. Cash generated by operating activities increased by \$1.5 million year-over-year. This was the result of (1) an increase in cash generated by operating activities before the impact of non-cash working capital of \$0.2 million and (2) an increase in cash generated by non-cash working capital of \$1.4 million for the three months ended March 31, 2020, relative to the comparative 2019 period.

The \$1.4 million increase in cash generated by non-cash working capital was due to increases in cash generated by (1) accounts payable and accruals (\$2.4 million), (2) interest payable (\$0.5 million), (3) due to related parties (\$0.3 million) and (4) prepaid expenses (\$0.2 million), which were offset by (5) a decrease in cash generated by accounts receivable (\$1.4 million) and (6) an increase in cash used in inventories (\$0.6 million).

Cash generated by investing activities was \$7.7 million during the first quarter of 2020, compared to \$nil cash generated in the first quarter of 2019. The \$7.7 million in cash generated by investing activities reflects a deposit received for the sale of one of the Company's idle facilities.

Cash used in financing activities was \$0.4 million in the first quarter of 2020, compared to \$0.1 million cash generated in the first quarter of 2019.

Financial Resources

Cash and cash equivalents increased by \$8.2 million for the three months ended March 31, 2020, relative to December 31, 2019. This increase was driven primarily by a deposit received (\$7.7 million) for the sale of one of the Company's idle facilities. Working capital decreased by \$17.4 million from the year-end 2019 position to negative \$181.8 million.

The working capital decrease of \$17.4 million is attributable to an increase in current liabilities of \$26.2 million, which was offset by an increase in current assets of \$8.8 million. The \$26.2 million increase in current liabilities was due to increases in (1) accounts payable and accruals (\$10.6 million), (2) short-term loans (\$6.7 million), (3) due to related parties (\$4.6 million), (4) interest payable (\$4.1 million) and (5) derivative liabilities (\$0.2 million). The \$8.8 million increase in current assets is attributable to increases in (1) cash (\$8.2 million), (2) inventories

(\$1.0 million) and (3) sales taxes recoverable (\$0.1 million), which were offset by (4) a decrease in accounts receivable (\$0.4 million).

The Company has been working on improving its working capital deficiency situation, which was driven by the impairments to inventory, accounts receivable, sales taxes recoverable and prepaid expenses over the years 2011 - 2019. See above section on Liquidity and Capital Resources for additional details on the Company's debt restructuring progress and new short-term loans.

The Company's working capital and working capital requirements fluctuate from quarter to quarter depending on, among other factors, the annual stevia harvest in China (third and fourth quarter each year) and the production output along with the amount of sales conducted during the period. The value of raw material in inventory has historically been the highest in the fourth quarter due to the fact that the Company purchases leaf during the third and fourth quarter and monk fruit during the fourth quarter for the entire production year, which runs October through September each year. The Company's principal working capital needs include accounts receivable, taxes receivable, inventory, prepaid expenses, other current assets, and accounts payable and interest payable.

Balance Sheet

As at March 31, 2020, in comparison to December 31, 2019, the total assets increased by \$11.1 million. This \$11.1 million increase was due to increases in current assets of \$8.8 million and fixed assets of \$2.3 million. Total liabilities increased by \$26.2 million as at March 31, 2020, in comparison to December 31, 2019.

Shareholders' deficiency increased by \$12.0 million due to (1) an increase in shareholders' deficit (\$8.7 million) and (2) a decrease in accumulated other comprehensive loss (\$3.5 million), which was offset by (3) an increase in share capital (\$0.1 million).

Short-Term Loans

The Company's short-term loans of \$68,824,187 (December 31, 2019 - \$62,092,012) consist of borrowings from an SOCMC and a bank in China of \$65,430,471 (December 31, 2019 - \$60,952,961) and loans from private lenders of \$3,393,716 (December 31, 2019 - \$1,139,051) as follows:

Loa	an amount in	Loan amount in		Interest rate per	
	CAD	RMB	Maturity Date	annum	Lender
\$	600,600	3,000,000	On Demand	9.26%	China Cinda Assets Management Anhui Branch
	5,605,600	28,000,000	On Demand	9.26%	China Cinda Assets Management Anhui Branch
	2,002,000	10,000,000	On Demand	8.56%	China Cinda Assets Management Anhui Branch
	1,957,956	9,780,000	On Demand	8.56%	China Cinda Assets Management Anhui Branch
	10,324,653	51,571,696	On Demand	7.78%	China Cinda Assets Management Anhui Branch
	16,016,000	80,000,000	On Demand	7.78%	China Cinda Assets Management Anhui Branch
	15,852,799	79,184,808	On Demand	11.97%	China Cinda Assets Management Anhui Branch
	3,494,987	17,457,477	On Demand	8.83%	China Cinda Assets Management Anhui Branch
	8,513	42,523	On Demand	8.83%	China Cinda Assets Management Anhui Branch
	1,061,060	5,300,000	July 31, 2020	5.82%	Huishang Bank
	6,006,000	30,000,000	On Demand	9.10%	China Cinda Assets Management Jiangsu Branch
	2,500,303	12,489,025	On Demand	9.10%	China Cinda Assets Management Jiangsu Branch
\$	65,430,471	326,825,529			

Bank loans as at March 31, 2020:

Bank loans as at December 31, 2019:

Loan amount in	Loan amount in		Interest rate	
CAD	RMB	Maturity Date	per annum	Lender
559,500	3,000,000	On Demand	9.57%	China Cinda Assets Management Anhui Branch
5,222,000	28,000,000	On Demand	9.57%	China Cinda Assets Management Anhui Branch
1,865,000	10,000,000	On Demand	8.56%	China Cinda Assets Management Anhui Branch
1,823,970	9,780,000	On Demand	8.56%	China Cinda Assets Management Anhui Branch
9,618,121	51,571,696	On Demand	7.77%	China Cinda Assets Management Anhui Branch
14,920,000	80,000,000	On Demand	7.77%	China Cinda Assets Management Anhui Branch
14,767,967	79,184,808	On Demand	11.97%	China Cinda Assets Management Anhui Branch
3,255,819	17,457,477	On Demand	8.83%	China Cinda Assets Management Anhui Branch
7,931	42,523	On Demand	8.83%	China Cinda Assets Management Anhui Branch
988,450	5,300,000	On Demand	5.82%	Huishang Bank
5,595,000	30,000,000	On Demand	12.12%	China Cinda Assets Management Jiangsu Branch
2,329,203	12,489,025	On Demand	9.09%	China Cinda Assets Management Jiangsu Branch
60,952,961	\$ 326,825,528			

The Company has been working with its Chinese banks and SOCMCs on restructuring its debt during the quarter ended March 31, 2020.

The assets of the Company's subsidiaries including inventory and property, plant and equipment have been pledged as collateral for these loans.

Short-term borrowing from private lenders:

December 31, 2018	\$ 1,049,487
Additions	139,875
Foreign currency translation	(50,311)
December 31, 2019	\$ 1,139,051
Additions	2,069,375
Foreign currency translation	 185,290
March 31, 2020	\$ 3,393,716

As at December 31, 2018, short-term borrowing from private lenders consisted of one US dollar denominated loan. During the year ended December 31, 2019 an additional loan was received which is denominated in Chinese renminbi ("RMB").

The US dollar loan is unsecured and bears interest at 11.50% per annum, compounding quarterly. The loan is due on demand. The RMB denominated loan is unsecured, bears interest at 5.82% per annum and is due on August 8, 2020.

During the three months ended March 31, 2020, the Company received four unsecured loans from private lenders that are denominated in RMB, bearing interest at 12% per annum and are due on January 5, 2021.

Financial and Other Instruments

The Company's financial instruments comprise cash and cash equivalents (classified as "held-for-trading"), accounts receivable and certain other assets that are financial instruments (classified as "loans and receivables"), and short-term loans, accounts payable, interest payable, advance from customer, due to related party, and noncurrent bank loans (classified as "other financial liabilities"). The Company currently does not have any hedge instruments.

As at March 31, 2020, the Company recorded cash and cash equivalents at fair value. Recorded amounts for accounts receivable, accounts payable and accrued liabilities, short-term loans, interest payable, advances from customers, and due to related party approximate their fair values due to the short-term nature of these instruments.

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. The Company's primary credit risk is on its cash and cash equivalents, restricted cash and accounts receivable.

The Company limits its exposure to credit risk by placing its cash and cash equivalents with various financial institutions. Given the current economic environment, the Company monitors the credit quality of the financial institutions it deals with on an ongoing basis.

The assets of the Company's subsidiaries including inventory and property, plant and equipment have been pledged as collateral for these loans.

The Company has a high concentration of credit risk as the majority of accounts receivable was owed by fewer than ten customers. However, the Company believes that it does not require collateral to support the carrying value of these financial instruments. The carrying amount of financial assets represents the maximum credit exposure. The Company reviews financial assets, including past due accounts, on an ongoing basis with the objective of identifying potential events or circumstances which could delay or prevent the collection of funds on a timely basis. Based on default rates on customers with receivable balances at March 31, 2020, the Company believes that there are minimal requirements for an allowance for doubtful accounts against its accounts receivable.

Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of a change in foreign exchange rates. The Company conducts its business primarily in US dollars, Chinese Renminbi ("RMB"), Canadian dollars and Hong Kong dollars. The Company is exposed to currency risk as the functional currency of its subsidiaries is other than Canadian dollars.

The majority of the Company's assets are held in subsidiaries whose functional currency is the RMB. The RMB is not a freely convertible currency. Many foreign currency exchange transactions involving RMB, including foreign exchange transactions under the Company's capital account, are subject to foreign exchange controls and require the approval of the PRC State Administration of Foreign Exchange. Developments relating to the PRC's economy and actions taken by the PRC government could cause future foreign exchange rates to vary significantly from current or historical rates. The Company cannot predict nor give any assurance of its future stability. Future fluctuations in exchange rates may adversely affect the value when translated or converted into Canadian dollars of the Company's net assets and net profits. The Company cannot give any assurance that any future movements in the exchange rates of RMB against the Canadian dollar and other foreign currencies will not adversely affect its results of operations, financial condition and cash flows. The Company does not use derivative instruments to reduce its exposure to foreign currency risk.

All of the Company's operations in China are considered self-sustaining operations. The assets and liabilities of the self-sustaining operations are translated at exchange rates prevailing at the balance sheet date.

See the Company's December 31, 2019, year-end consolidated financial statements (Note 25) for further information on its financial and other instruments.

Lease Liabilities

			Production	
	Office	Land	equipment	Total
At December 31, 2019	433,599	43,594	165,500	642,693
Lease payments made	(32,010)	(2,203)	(24,787)	(59,000)
Interest expense on lease liabilities	16,062	1,959	7,186	25,207
	417,651	43,350	147,899	608,900
Less: current portion	(70,081)	(1,420)	(78,821)	(150,322)
Non-current portion as at March 31, 2020	347,570	41,930	69,078	458,578

Capital Structure

Outstanding Share Data as at the date of this MD&A:

	31-Mar-20	31-Dec-19
Common Shares Issued	38,394,223	38,394,223
Stock Options	-	622,000
Total Reserved For Issuance	-	622,000
Fully Diluted Shares	38,394,223	39,016,223

Off-Balance Sheet Arrangements

The Company had no off-balance sheet arrangements.

Non-Controlling Interests

During the year ended December 31, 2017, the Company disposed of 32.92% of its ownership in Runhai to certain related parties and a private lender in order to settle \$15,971,767 (RMB 80,584,090) in related party loans and short-term loans. Accordingly, the Company de-recognized the derivative liabilities related to this portion of the loans totaling \$274,538. The reduction in the Company's ownership interest in Runhai did not result in a loss of control and was recorded as an equity transaction. In connection with the recognition of non-controlling interest, the proportionate share of the cumulative amount of foreign exchange translation differences recognized in other comprehensive income totaling \$3,649,111 was re-attributed to the noncontrolling interest in Runhai. In addition, the Company incurred transaction costs totaling \$563,154 and this amount was deducted from equity.

On June 1, 2018, the Company transferred its 100% ownership interest in its subsidiary Qingdao Runde Biotechnology Company, Ltd. ("Runde") to Runhai. As the Company has a 67.08% interest in Runhai, , the effect of this transfer was a disposition of 32.92% of its ownership interest in Runde. The reduction in the Company's ownership interest in Runhai did not result in a loss of control and was recorded as an equity transaction. As a result of this transaction, Runhai has sole ownership of all other China subsidiaries and the Company continues to own 67.08% of Runhai. The carrying amount of non-controlling interests was adjusted to reflect the change in the non-controlling interests' relative interests in the subsidiary and the difference between the adjustments to

the carrying amount of non-controlling interests and the Company's share of proceeds received and/or consideration paid is recognized directly in equity and attributed to shareholders of the Company.

The following table summarizes the consolidated assets and liabilities of Runhai and the share of the net liabilities which are attributable to the non-controlling interest as at March 31, 2020, and December 31, 2019:

	March 31, 2020	Dec	ember 31, 2019
ASSETS			
Current	\$ 13,970,546	\$	5,433,912
Non-current	30,709,753		28,379,295
	\$ 44,680,299	\$	33,813,207
LIABILITIES			
Current	\$ 141,389,810	\$	121,340,827
	\$ 141,389,810	\$	121,340,827
Netliabilities	\$ (96,709,511)	\$	(87,527,620)
Non-controlling interest percentage	32.92%		32.92%
Non-controlling interest in net liabilities	\$ (31,836,771)	\$	(28,814,093)

Transactions with Related Parties

a) Amount due to related parties

Amounts due to related parties are summarized as follows:

	Note	March 31, 2020	December 31, 2019
Loans from Chief Executive officer ("CEO")		\$ 8,497,602	\$ 7,547,163
Loans from direct family member of CEO		31,049,027	27,809,675
	i)	39,546,629	35,356,838
Consulting fees payable to CEO	ii)	3,533,712	3,136,431
Loan from Director of the Company	iii)	 1,037,500	1,037,500
		\$ 44,117,841	\$ 39,530,769

The loans from the CEO and close family member are summarized as follows:

Loan amount in Date of the Loan Interest rate per Maturity Date Security **Related Parties** CAD Agreement annum 709,421 April 27, 2012 On demand Unsecured Category 1 Chairman and CEO Category 1 1,418,700 October 11, 2012 On demand Unsecured Chairman and CEO 709,350 May 30, 2013 On demand Unsecured Category 1 Chairman and CEO 354,675 November 15, 2013 On demand Unsecured Category 1 Chairman and CEO 978,903 October 20, 2014 On demand Unsecured Category 2 Direct family member of CEO 205,712 May 23, 2017 On demand Unsecured Category 2 Direct family member of CEO 1,397,316 August 28, 2017 On demand Unsecured Category 3 Direct family member of CEO 2,638,782 August 7, 2018 On demand Unsecured Category 3 Direct family member of CEO 709,350 November 27, 2018 On demand Unsecured Category 4 Direct family member of CEO Principal 9,122,209 Accrued interest 30,424,420 39,546,629

Category 1: US 10 year benchmark government bond rate plus 1100 basis points annual interest rate for loans issued in USD or

China 10 year benchmark government bond rate plus 1100 basis points annual interest rate for loans issued in RMB, compounding quarterly

Category 2: 20% annual interest rate, compounding quarterly Category 3: 18% annual interest rate, compounding quarterly

Category 4: 20% simple interest

Loan balance as of December 31, 2019

Loan balance as of March 31, 2020

	Loan amount in CAD		Date of the Loan Agreement	Maturity Date	Security	Interest rate per annum	Related Parties
	\$	649,465	April 27, 2012	On demand	Unsecured	Category 1	Chairman and CEO
		1,298,800	October 11, 2012	On demand	Unsecured	Category 1	Chairman and CEO
		649,400	May 30, 2013	On demand	Unsecured	Category 1	Chairman and CEO
		324,700	November 15, 2013	On demand	Unsecured	Category 1	Chairman and CEO
		896,172	October 20, 2014	On demand	Unsecured	Category 2	Direct family member of CEO
		188,326	May 23, 2017	On demand	Unsecured	Category 2	Direct family member of CEO
		1,430,175	August 28, 2017	On demand	Unsecured	Category 3	Direct family member of CEO
		2,415,768	August 7, 2018	On demand	Unsecured	Category 3	Direct family member of CEO
		649,400	November 27, 2018	On demand	Unsecured	Category 4	Direct family member of CEO
Principal	\$	8,502,206					
Accrued interest		26,854,632					
	\$	35,356,838					

Category 1: US 10 year benchmark government bond rate plus 1100 basis points annual interest rate for loans issued in USD or

China 10 year benchmark government bond rate plus 1100 basis points annual interest rate for loans issued in RMB, compounding quarterly

Category 2: 20% annual interest rate, compounding quarterly

Category 3: 18% annual interest rate, compounding quarterly

Category 4: 20% simple interest

i. The Company obtained loans under numerous credit facility agreements from the Company's Chairman and Chief Executive Officer ("CEO"). As at March 31, 2020, the total amount owed to the CEO under these facilities, including principal and accumulated interest is \$8,497,602 (2019 - \$7,547,163). As at March 31, 2020, the entire balance owed is due within 12 months and is therefore classified as current on the statement of financial position.

The Company also obtained loans under numerous credit facility agreements from a direct family member of the CEO. As at March 31, 2020, the total amount owed under these facilities, including principal and

accumulated interest is \$31,049,027 (2019 - \$27,809,675). As at March 31, 2020, the entire balance owed is due within 12 months and is therefore classified as current on the statement of financial position.

The combined total of the above loans, including the accrued interest, is \$39,546,629 (2019 - \$35,356,838). These loans will be repaid by either GLG or its Chinese subsidiaries to the lender in the currency the loans were originally borrowed (either USD or RMB), or, at the lender's discretion, in either USD or RMB, depending on the terms of the specific credit facility. The terms of each individual loan are disclosed in the table below.

These loans provide a repayment option to the lenders in either RMB or USD using a fixed foreign exchange rate specified in each credit facility. This option results in a liability of \$707,052 (2019 - \$521,468), which is comprised of a derivative liability and an unrealized foreign exchange loss. The fair value of the derivative liability was calculated using the Black-Scholes model with the following assumptions:

	2020	2019
Risk free interest	1.61%	2.02%
Expected life of the loan	1 year	1 year
Expected foreign currency volatility	3.67%	3.27%

- ii. As of March 31, 2020, the Company has accrued \$3,533,712 (2019 \$3,136,431), including 3% interest per annum compounding quarterly, in consulting fees to the Company's Chairman and Chief Executive Officer.
- iii. During 2020, the Company had renewed a loan of \$1,000,000 (2019 \$1,000,000) from a Director of the Company originally borrowed to provide working capital required for Monk Fruit extracts. The loan is secured by expected proceeds from monk fruit sales, bearing interest at 15% per annum and repayable in full on March 31, 2021. As of March 31, 2020, the total amount due to this related party, including interest was \$1,037,500 (2019 \$1,037,500).

b) Transactions with key management personnel

Key management personnel are those persons who have the authority and responsibility for planning, directing, and controlling activities of the Company directly or indirectly, including any external directors of the Company.

Remuneration of key management of the Company is comprised of the following amounts:

	Three months ended March 31			
		2020		2019
Short-term employee benefits (including salaries, bonuses, fees and social security benefits)	Ś	356,692	Ś	380,162
Share-based benefits	\$,	\$	146,858
Total remuneration	\$	506,133	\$	527,020

Certain executive officers are subject to termination benefits. Upon resignation at the Company's request or in

the event of a change in control, they are entitled to termination benefits equal to 36 months of gross salary, totaling approximately US \$1,794,000.

Key management did not exercise stock options granted under the Company's stock option plan in the three months ended March 31, 2020.

Disclosure Controls and Internal Controls over Financial Reporting

The Company's disclosure controls and procedures are designed to provide reasonable assurance that relevant information relating to the Company, including its consolidated subsidiaries, is made known to senior management in a timely manner so that information required to be disclosed by the Company under securities legislation is recorded, processed, summarized and reported within the time periods specified in applicable securities legislation. As of the end of the period covered by this report, the Company's management evaluated, under the direction and supervision of the Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of the Company's disclosure controls and procedures, as defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim filings ("NI 52-109"). The Company's disclosure controls and procedures and procedures were effective to ensure that information required to be disclosed in reports the Company files or submits to the Canadian Securities Administrators ("CSA") is recorded, processed, summarized and reported within the time periods specified therein and accumulated and reported to management to allow timely discussions regarding required disclosure.

The Company's management, under the direction and supervision of the Chief Executive Officer and Chief Financial Officer, is also responsible for establishing and maintaining internal control over financial reporting. These controls are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in Canada.

Management assessed the effectiveness of the Company's internal control over financial reporting, as defined in NI 52-109, as of March 31, 2020. In making this assessment, management used the criteria set forth in the "Internal Control – Integrated Framework" issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, the Company's Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2020, the Company's internal control over financial reporting were effective.

It should be noted that while the officers of the Company have certified the Company's period - end filings, they do not expect that the disclosure controls and procedures or internal controls over financial reporting will prevent all errors and fraud. A control system, no matter how well conceived or implemented, can only provide reasonable, not absolute, assurance that the objectives of the control system are met.

Risks Related to the Company's Business

This section describes the material risks affecting the Company's business, financial condition, operating results and prospects. A prospective investor should carefully consider the risk factors set out below and consult with his, her or its investment and professional advisors before making an investment decision. There may be other risks and uncertainties that are not known to the Company or that the Company currently believes are not material, but which also may have a material adverse effect on the Company's business, financial condition, operating results or prospects. In that case, the trading price of the common shares could decline substantially, and investors may lose all or part of the value of the common shares held by them. There are a number of risk factors that could materially affect the business of GLG, which include but are not limited to the risk factors set out below. The Company has been structured to minimize these risks. More details about the following risk factors can be found in the Company's Annual Information Form filed on SEDAR at <u>www.sedar.com</u>.

- Intellectual Property Infringement
- Product Liability Costs
- Manufacturing Risk
- Inventory Risk
- Customer Concentration Risk
- Competition
- Government Regulations
- Consumer Perception of Products
- Changing Consumer Preferences
- Market Acceptance
- Dependence on Key Personnel
- Volatility of Share Prices

Risks Associated with Doing Business in the People's Republic of China

The Company faces the following additional risk factors that are unique to it doing business in China. More details about the following risk factors can be found in the Company's Annual Information Form.

- Government Involvement
- Changes in the Laws and Regulations in the People's Republic of China
- The Chinese Legal and Accounting System
- Currency Controls
- Additional Compliance Costs in the People's Republic of China
- Difficulties Establishing Adequate Management, Legal and Financial Controls in the People's Republic of China
- Capital Outflow Policies in the People's Republic of China
- Jurisdictional and Enforcement Issues
- Political System in the People's Republic of China

Additional Information

Additional information relating to the Company, including our Annual Information Form, is available on SEDAR (<u>www.sedar.com</u>). Additional information relating to the Company is also available on our website (<u>www.glglifetech.com</u>).